Bebtelovimab Available for Purchase 8/15
Federally funded distribution of Bebtelovimab to states will end in mid-August. After federal distribution to states ends, Bebtelovimab will become available commercially, and DSHS will stop allocation.
Bebtelovimab will be available for purchase beginning August 15, 2022. The cost, reimbursement, and purchase details have not been released yet; we will provide additional information next week. CMS will post reimbursement cost here when it is available.
Providers should submit requests for Bebtelovimab in HPOP. DSHS will complete the final allocation of available product during the week of August 15, 2022. Read the 7/21 communication for more information.
New Evusheld Helpline for Providers
AstraZeneca has established a helpline to receive additional general product information as well as specific guidance on how to access the product, including information on ordering.
1-833-EVUSHLD (1-833-388-7453)
In addition, ASPR has opened a new route for providers who are not enrolled as a COVID-19 therapeutics provider in HPOP to obtain 1-3 courses of Evusheld for their patients. Providers may request small quantities directly from the manufacturer using this form.
For additional information, see ASPR: New Helpline and Ordering Pathway for Evusheld.
Note: There is a new JAMA Patient Page for Evusheld
Reminder! Updated Paxlovid Fact Sheet and FDA Checklist
The Paxlovid Fact Sheet for Healthcare Providers and the Paxlovid Patient Eligibility Screening Checklist Tool for Prescribers (FDA) were recently updated. The checklist now includes information specific to the pharmacists who may prescribe Paxlovid. The list of drugs that may have contradictions or interactions with Paxlovid has also been updated.
Note: PAXLOVID is not authorized for use for longer than 5 consecutive days.
US HHS/ASPR Weekly Therapeutics Meetings
US HHS/ASPR hosts two weekly meetings about therapeutics, taking place on Wednesday and Friday.
The Allocation, Distribution, and Administration of COVID-19 Therapeutics meeting is unstructured time where providers can pose questions to the team.
- Wednesdays, 2:15 – 3:15 pm CT
The Therapeutics Weekly Clinical Rounds meeting is a webinar on topics that change each week to reflect the most recent issues. A question-and-answer period follows the presentations.
- Fridays, 11:00 am – 12:00 pm CT
Email COVID19Therapeutics@HHS.gov to request invitations and links.
Reporting Evusheld in HPOP
Differing from the other products, Evusheld is reported by the number of cartons instead of patient courses.
To stay consistent with historical reporting, continue to report Evusheld inventory and administrations per 300 mg units (1 carton).
- Administration reporting should always be an even number
-
ONE patient dose with 600 mg should be reported as “2” administrations
-
TWO patients dosed -> report in HPOP as “4” (2 patients, 4 cartons, 8 vials)
-
SIX patients dosed -> report in HPOP as “12” (6 patients, 12 cartons, 24 vials)
If you have been reporting ONE administration per patient and need assistance updating your previous administration data, email DSHS Therapeutics at therapeutics@dshs.texas.gov.
Shelf-Life Extensions
Many COVID-19 therapeutics have received expiration date extensions. Please check with the manufacturer before removing any products from the proper storage conditions.
See links below for detailed expiry information:
Also see the FDA’s approach to COVID-19 Therapeutics shelf-life extensions here.
Maintain all monoclonal antibodies under proper refrigerated temperatures, even if they are not currently authorized for use. It is expected that will be authorized again in the future for use against new strains of SARS-COV2.
|
